Evolus (EOLS) said Monday that it will launch Estyme, its injectable hyaluronic acid gel collection, in Europe on May 16.
The company said that the Estyme collection includes four injectable hyaluronic acid gels, including its Estyme Sculpt product, which has been developed to restore mid-face volume.
Evolus said that the commercial launch in the region follows its successful CE Mark certification under the European Medical Device Regulation.
Shares of the company were up 3% in early Monday trading.
Price: 6.55, Change: +0.19, Percent Change: +2.91
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments